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Background. The pathogenesis of sepsis is mediated in part by bacterial endotoxin, which stimulates macrophages/
monocytes to sequentially release early (e.g., TNF, IL-1, and IFN-c) and late (e.g., HMGB1) pro-inflammatory cytokines. Our
recent discovery of HMGB1 as a late mediator of lethal sepsis has prompted investigation for development of new
experimental therapeutics. We previously reported that green tea brewed from the leaves of the plant Camellia sinensis is
effective in inhibiting endotoxin-induced HMGB1 release. Methods and Findings. Here we demonstrate that its major
component, (-)-epigallocatechin-3-gallate (EGCG), but not catechin or ethyl gallate, dose-dependently abrogated HMGB1
release in macrophage/monocyte cultures, even when given 2–6 hours post LPS stimulation. Intraperitoneal administration of
EGCG protected mice against lethal endotoxemia, and rescued mice from lethal sepsis even when the first dose was given
24 hours after cecal ligation and puncture. The therapeutic effects were partly attributable to: 1) attenuation of systemic
accumulation of proinflammatory mediator (e.g., HMGB1) and surrogate marker (e.g., IL-6 and KC) of lethal sepsis; and 2)
suppression of HMGB1-mediated inflammatory responses by preventing clustering of exogenous HMGB1 on macrophage cell
surface. Conclusions. Taken together, these data suggest a novel mechanism by which the major green tea component,
EGCG, protects against lethal endotoxemia and sepsis.
Citation: Li W, Ashok M, Li J, Yang H, Sama AE, et al (2007) A Major Ingredient of Green Tea Rescues Mice from Lethal Sepsis Partly by Inhibiting
HMGB1. PLoS ONE 2(11): e1153. doi:10.1371/journal.pone.0001153
INTRODUCTION
Sepsis is a systemic inflammatory response syndrome resulted from
a microbial infection. As a continuum of increasing clinical
severity, severe sepsis is defined as sepsis associated with one or
more acute organ dysfunctions [1]. Despite recent advances in
antibiotic therapy and intensive care, sepsis is still the most
common cause of death in the intensive care units, claiming
approximately 225,000 victims annually in the U.S. alone. The
pathogenesis of sepsis is attributable, at least in part, to dys-
regulated systemic inflammatory responses characterized by
excessive accumulation of various proinflammatory mediators
such as interleukin (IL)-1 [2], interferon (IFN)-c [3], nitric oxide
[4,5], and macrophage migration inhibitory factor (MIF) [6].
We recently discovered that a ubiquitous protein, high mobility
group box 1 (HMGB1), is released by activated macrophages/
monocytes [7–10], and functions as a late mediator of lethal
endotoxemia and sepsis [7,11–13]. Circulating HMGB1 levels are
elevated in a delayed fashion (after 16–32 h) in endotoxemic and
septic mice [7,11], and in patients with sepsis [7,14,15]. Adminis-
tration of recombinant HMGB1 to mice recapitulates many clinical
signs of sepsis, including fever [16,17], derangement of intestinal
barrier function [18], and tissue injury [19,20]. In contrast, anti-
HMGB1 antibodies or inhibitors (e.g., tanshinones, ethyl pyruvate,
nicotine, or stearoyl lysophosphatidylcholine) significantly protect
mice against LPS-induced acute tissue injury [19,20], and lethal
endotoxemia [7,11–13,21–23]. Notably, these anti-HMGB1 re-
agents are capable of rescuing mice from lethal experimental sepsis
even when the first doses are given 24 h after the onset of the disease
[11–13,21,23], indicating a wider window for HMGB1-targeted
therapeutic strategies. Therefore, agents proven clinically safe, and
yet still capableof attenuating HMGB1 release mayholdpotential in
the prevention and treatment of inflammatory diseases.
Throughout human history, herbal medicine has formed the basis
offolkremediesforvariousinflammatoryailments.Theuseofwillow
bark extract to reduce pain and fever was documented by a Greek
physician (Hippocrates) in the 5
th century BC, and the subsequent
discovery of salicylic acid as its pain/fever-relief active component
gave rise to the first synthetic anti-inflammatory drug, aspirin, and
the birth of the pharmaceutical industry. Brewed from the leaves of
the plant, Camellia sinensis, tea has been one of the most popular
beverages for almost fifty centuries. Its daily consumption
(,120 ml/person) is second only to water [24], and has been
associated with many important health benefits, such as reduction of
risk of oxidative stress and damage [25], atherosclerosis [25], cancer
[26], and cardiovascular diseases [27]. These healing properties of
green tea are attributable to its abundant polyphenolic compounds
known as catechins, such as (-)-epigallocatechin-3-gallate (EGCG), (-
)-epicatechin-3-gallate (EG), (-)-epigallocatechin (EGC), and (-)-
epicatechin (EC). Among them, EGCG accounts for 50-80% of
the total catechin, representing approximately 50 mg in a single cup
(100 ml) of green tea [28]. However, it was previously unknown if
green tea catechins can attenuate endotoxin-induced HMGB1
release or cytokine activities. In this study, we evaluated the capacity
of tea catechins in inhibiting endotoxin-induced HMGB1 release
and/or cytokine activities, and explored their therapeutic potential
in animal model of sepsis.
Academic Editor: Maurizio Del Poeta, Medical University of South Carolina, United
States of America
Received August 6, 2007; Accepted October 16, 2007; Published November 7,
2007
Copyright:  2007 Li et al. This is an open-access article distributed under the
terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author
and source are credited.
Funding: This research was supported by the National Institute of General
Medical Sciences grants (R01GM063075 and R01GM070817, to H.W.). The funder
had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests
exist.
* To whom correspondence should be addressed. E-mail: hwang@nshs.edu
PLoS ONE | www.plosone.org 1 November 2007 | Issue 11 | e1153METHODS
Cell culture
Murine macrophage-like RAW 264.7 cells were obtained from the
American Type Culture Collection (ATCC, Rockville, MD), and
primary peritoneal macrophages were isolated from Balb/C mice
(male, 7–8 weeks, 20–25 grams) at 2–3 days after intraperitoneal
injection of 2 ml thioglycollate broth (4%) as previously described
[8,12,23]. Murine macrophages were pre-cultured in RPMI 1640
medium (Gibco BRL, Grand Island, NY) supplemented with 10%
fetal bovine serum (FBS) and 2 mmol/L glutamine. Human
peripheral blood mononuclear cells (HuPBMCs) were isolated
from the blood of healthy donors (Long Island Blood Bank,
Melville, NY) by density gradient centrifugation through Ficoll
(Ficoll-Paque PLUS, Pharmacia, Piscataway, NJ), and cultured in
RPMI 1640 supplemented with 10% heat-inactivated human
serum/2 mM L-glutamine as previously described [8,12].
LPS stimulation
Adherent macrophages or monocytes were gently washed with,
and cultured in, serum-free OPTI-MEM I medium two hours
before stimulation with bacterial endotoxin (lipopolysaccharide,
LPS, E. coli 0111:B4, Sigma-Aldrich). At 16 hours after LPS
stimulation, levels of TNF, nitric oxide, and HMGB1 in the
culture medium were determined as previously described [8,12].
Chemical sources and stock solutions
Epigallocatechin gallate (EGCG, C22H18O11), catechin (C,
C15H14O6), or ethyl gallate (C9H10O5) were obtained from the
Sigma (St. Louis, MO), and 10 mM stock solutions were prepared
in water.
Animal models of endotoxemia and sepsis
This study was approved and performed in accordance with the
guidelines for the care and use of laboratory animals at the Feinstein
Institute for Medical Research, Manhasset, New York. Endotoxemia
was induced in Balb/C mice (male, 7–8 weeks) by intraperitoneal
injection of bacterial endotoxin (LPS, 15 mg/kg) as previously
described [7,12,23]. Sepsis was induced in male Balb/C mice (7–
8 weeks, 20–25 g) by cecal ligation and puncture (CLP) as previously
described [12,23]. EGCG was administered intraperitoneally into
m i c ea ti n d i c a t e dd o s e sa n dt i m ep o i n t s ,a n dm i c ew e r em o n i t o r e df o r
survival for up to two weeks. In parallel experiments, mice were
euthanized to collect blood at 52 h (following two doses of EGCG at
+24 and +48 h) after CLP, and assayed for serum levels of TNF,
HMGB1, and other cytokines. In other parallel experiments, blood
was collected from 3–5 normal healthy mice, or septic mice
appearing dying (i.e., in a moribund state, as judged by: 1) unresponsive to
externalstimuli; 2)inabilitytomaintainuprightposition;and3)agonalbreathing]
or non-dying (i.e., in a non-moribund state, as indicated by: 1) responsive to
external stimuli; 2) ability to maintain upright position; and 3) normal breathing]
at 52 h post CLP, and serum levels of cytokines were determined.
TNF ELISA
The levels of TNF in the culture medium or serum were determined
using commercial enzyme linked immunosorbant assay (ELISA) kits
(Catalog no. MTA00, R & D Systems, Minneapolis, MN) with
reference to standard curves of purified recombinant TNF at various
dilutions as previously described [12,23].
Nitric oxide assay
The levels of nitric oxide in the culture medium were determined
indirectly by measuring the NO
22 production with a colorimetric
assay based on the Griess reaction [12,23]. NO
22 concentrations
were determined with reference to a standard curve generated
with sodium nitrite at various dilutions.
HMGB1 Western blotting analysis
The levels of HMGB1 in the culture medium or serum were
determined by Western blotting analysis as previously described
[7,8,12,23]. The relative band intensity was quantified by using
the NIH image 1.59 software to determine HMGB1 levels with
reference to standard curves generated with purified HMGB1.
Cytokine antibody array
Murine cytokine antibody array (Cat. No. M0308003, RayBiotech
Inc., Norcross, GA, USA), which detects 62 cytokines on one
membrane, was used to determine the profile of cytokines in the
culture medium or serum as previously described [12]. Briefly, the
membranes were sequentially incubated with equal volume of cell-
conditioned culture medium, or murine serum (after 1:10 dilution),
primary biotin-conjugated antibodies, and horseradish peroxidase–
conjugated streptavidin. After exposing to X-ray film, the relative
signal intensity was determined using the NIH image 1.59 software,
and expressed as % of positive controls on the same membrane.
Cell Viability Assays
Cell viability was assessed by trypan blue exclusion assays as
previously described [8]. Briefly, trypan blue was added to cell
cultures at a final concentration of 0.08%. After incubation for
5 min at 25uC, cell viability was assessed by the percentage of dye-
excluding cells in five 406microscope fields.
Expression and purification of recombinant HMGB1
The cDNA encoding for rat HMGB1 was cloned onto a pCAL-n
vector, and the recombinant plasmid was transformed into E. coli
BL21 (DE3) pLysS cells as previously described [7]. Recombinant
HMGB1 containing a ,3 kDa calmodulin-binding peptide tag
(CBP-HMGB1 fusion protein, 33 kDa) was expressed in E. coli,
and purified to remove contaminating endotoxin using polymyxin
B column as previously described [7,29,30]. Recombinant
HMGB1 preparations were tested routinely for LPS content by
the chromogenic Limulus amebocyte lysate assay (Endochrome;
Charles River), and endotoxin content was below detection limit
(,500 pg endotoxin per microgram of rHMGB1). Recombinant
HMGB1 was biotinylated using a Pierce EZ-Link Sulfo-NHS-LC-
Biotinylation Kit (Cat. # 21430) following the manufacturer’s
protocol. The sulfonated NHS esters are cell membrane-imperme-
able, and are therefore suitable for cell-surface binding/uptake
studies. Subsequently, the biotinylated protein was purified by gel
filtration chromatography using Sephadex G-25 column.
Fluorescence Immunostaining
RAW 264.7 cells were grown to subconfluence, and incubated with
biotinylated HMGB1, in the absence or presence of EGCG (10 mM)
for various period of time. Subsequently, cells were fixed with 2%
formalin for 10 min, and permeabilized with 0.1% Triton X-100 in
PBS (1 min, room temperature). After extensive washing with PBS,
cells were incubated sequentially with antigen-affinity-purified rabbit
anti-HMGB1 antibodies, and goat anti-rabbit secondary antibodies
conjugated with green Alexa fluor 488 (Molecular Probes, Eugene,
OR). To visualize exogenous HMGB1, cells were co-incubated with
streptavidin-conjugated Alexa fluor 594 or Alexa fluor 488
(Molecular Probes). Images were captured using a fluorescence
microscope (Carl Zeiss Microimaging).
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Cell lysates were incubated with streptavidin agarose beads (Cat.#
15942-050, Invitrogen) for 1.5 h at 4uC on a rotating platform.
After centrifugation, agarose beads were washed six times with
16PBS, and bound proteins were eluted with Laemmili sample
buffer (Cat. # 161-0737, Bio-Rad), and analyzed by SDS-PAGE
and Western blotting with anti-HMGB1 antibodies.
Statistical Analysis
Data are expressed as mean6SD of two independent experiments
in triplicates (n=2). One-way ANOVA was used for comparison
among all different groups. When the ANOVA was significant,
post-hoc testing of differences between groups was performed
using Tukey’s test. The Kaplan-Meier method was used to
compare the differences in mortality rates between groups. A
P,value less than 0.05 was considered statistically significant.
RESULTS
Tea epigallocatechin gallate (EGCG) dose-
dependently attenuated endotoxin-induced release
of HMGB1, but not nitric oxide
We previously discovered that green tea brewed from the leaves of
the plant, Camellia sinensis, is effective in inhibiting endotoxin-
induced HMGB1 release [31]. To determine active components in
green tea, we examined its components for HMGB1-inhibiting
activities in murine macrophage-like RAW264.7 cells. A major tea
catechin, EGCG, dose-dependently abrogated endotoxin-induced
HMGB1 release, with an estimated IC50,1.0 mM( Fig. 1A). In
contrast, at concentrations that abrogated endotoxin-induced
HMGB1 release, EGCG only partially attenuated endotoxin-
induced TNF secretion (Fig. 1B), but did not inhibit endotoxin-
induced nitric oxide release (Fig. 1C).
We further confirmed its HMGB1-inhibiting activities using
primary murine peritoneal macrophages (MuMACs), as well as
human peripheral blood mononuclear cells (huPBMCs). In primary
MuMACs, EGCG also abrogated LPS-induced HMGB1 release,
but similarly failed to inhibit LPS-induced nitric oxide release
(Fig. 2A). In primary huPBMCs, EGCG effectively abolished LPS-
induced HMGB1 release (Fig. 2B), and partly attenuated LPS-
induced TNF secretion (Fig. 2B). Taking together, these data
suggest that EGCG is capable of effectively inhibiting LPS-induced
HMGB1 release in both macrophage and monocyte cultures.
To better understand EGCG’s anti-inflammatory properties, we
employed cytokine antibody array to examine its effects on LPS-
induced release of multiple cytokines. At concentrations (15 mM)
that completely abrogated LPS-induced HMGB1 release, EGCG
did not affect LPS-induced release of G-CSF, IL-1a,P - s e l e c t i n ,o r
LIX in primary MuMACs (Fig. 2C). Consistent with few previous
reports [32,33],cytokine antibodyarray analysis revealed a dramatic
suppression of LPS-induced release of TNF and IL-12 in primary
MuMACs (Fig. 2C). Furthermore, EGCG dramatically inhibited
LPS-induced release of IL-6, and a number of chemokines including
MIP-1a,M I P - 1 c,M I P - 2 ,R A N T E S ,K C ,M C P 1 ,a n dC X C L 1 6
(Fig. 2C). Taken together, these experimental data suggest that
EGCG selectively inhibits LPS-induced release of HMGB1, TNF,
IL-6, IL-12, and chemokines, without affecting LPS-induced release
of G-CSF, P-selection, LIX, IL-1a or nitric oxide.
Delayed administration of EGCG still attenuated
endotoxin-induced HMGB1 release
As compared with early proinflammatory cytokines (such as TNF),
HMGB1 is released late following endotoxin stimulation [7]. It is
intriguing to consider whether EGCG could inhibit HMGB1 release
if added after LPS stimulation. Whereas concurrent administration
of EGCG was most effective in inhibiting LPS-induced HMGB1
release, significant inhibition was still achieved when it was added 2
to 6 h after LPS (Fig. 3). It thus becomes feasible to attenuate late-
acting proinflammatory mediators (such as HMGB1) by strategically
administering EGCG in a delayed fashion.
Determination of structure-function relationships
As a class of biologically active polyphenols, catechins contain two or
more aromatic rings (each carrying at least one aromatic hydroxyl)
connected with a carbon bridge (consisting of five carbons and one
oxygen, Fig. 4A). To gain insights into the structure-function
relationships, we compared the HMGB1-inhibiting activities
Figure 1. EGCG effectively abrogated endotoxin-induced HMGB1
release in murine macrophage-like RAW 264.7 cells. RAW 264.7 cells
were stimulated with LPS in the absence, or presence of EGCG at
indicated concentrations. At 16 hours after LPS stimulation, levels of
HMGB1 (Panel A), TNF (Panel B), or nitric oxide (NO, Panel C) in the
culture medium were determined by Western blotting, ELISA, and
Griess reaction, respectively. Note that at concentrations that com-
pletely abrogated LPS-induced HMGB1 release (Panel A), EGCG only
partially inhibited LPS-induced TNF secretion (Panel B), but preserved
suppress LPS-induced nitric oxide release (Panel C).
doi:10.1371/journal.pone.0001153.g001
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gallate (Fig. 4A). Even at concentrations up to 10 mM, catechin or
ethyl gallate did not affect LPS-induced HMGB1 release (Fig. 4B),
indicating that functional groups of both catechin and gallate are
needed for EGCG’s HMGB1-inhibiting properties.
EGCG protected mice against lethal endotoxemia
In light of the capacity of EGCG in attenuating LPS-induced
HMGB1 release, we explored its efficacy in animal model of lethal
endotoxemia. By treating animals with three doses of EGCG at
20.5, +24, and +48 hours post intraperitoneal administration of
L.D.50 dose of LPS, we observed a significant improvement in
animal survival rate (from 50% to 76%, P,0.05, Fig. 5A),
confirming a previous observation that mixture of tea catechins
improvedsurvivalrateat24 hourpostonsetofendotoxemia[32,33].
EGCG rescues mice from lethal sepsis
Although endotoxemia is useful for investigating the complex
cytokine cascades, more clinically relevant animal models are
necessary to explore therapeutic agents for the treatment of
Figure 2. EGCG effectively abrogated endotoxin-induced HMGB1 release in primary macrophage/monocyte cultures. Primary murine peritoneal
macrophages (Panel A, C), or human peripheral blood mononuclear cells (Panel B) were stimulated with LPS in the absence, or presence of EGCG
(15 mM). At 16 hours after LPS stimulation, levels of HMGB1 (Panel A, B), nitric oxide (Panel A), TNF (Panel B), or other cytokines (Panel C) in the
culture medium were determined by Western blotting analysis (Panel A, B, top), Griess reaction (Panel A, bottom), ELISA (Panel B, bottom), or
cytokine array (Panel C), respectively. Note that at concentrations that completely abrogated LPS-induced HMGB1 release, EGCG did not block LPS-
induced release of NO (Panel A), G-CSF (Panel C), IL-1a (Panel C), P-selectin (Panel C), or LIX (Panel C). In contrast, EGCG dramatically suppressed LPS-
induced release of TNF, sTNF-RII, chemokines (MCP1, MIPs, KC, and RABTES), IL-6, IL-12, and CXCL16 in primary murine macrophages (Panel C). Shown
in Panel C was a representative cytokine array of two independent experiments with similar results.
doi:10.1371/journal.pone.0001153.g002
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of sepsis is induced by CLP. In light of the late and prolonged
kinetics of HMGB1 accumulation in experimental sepsis [11], we
reasoned that it might be possible to rescue mice from lethal sepsis
even if EGCG is administered after the onset of sepsis. The first
dose of EGCG was given 24 h after the onset of sepsis, a time
point at which mice developed clear signs of sepsis (including
lethargy, diarrhea, and piloerection). Repeated administration of
EGCG beginning twenty-four hours after the onset of sepsis
(followed by additional doses at 48, and 72 hours post sepsis)
conferred a dose-dependent protection against lethal sepsis
(N=22-32 mice per group, Fig. 5B), significantly increasing
animal survival rate from 53% to 82% (P,0.05), supporting
a therapeutic potential for EGCG in the treatment of sepsis.
EGCG attenuates sepsis-induced systemic HMGB1
accumulation
To gain insight into its protective mechanism, we evaluated the
effects of EGCG on the systemic accumulation of various cytokines
by cytokine antibody array, ELISA, and Western blotting analysis.
Delayed administration of EGCG did not affect the circulating levels
of most cytokines (Fig. 6A), but significantly attenuated circulating
levelsof IL-6 (83.564.5% of positive controls, ‘‘CLP+Saline’’; versus
20.0611.0% of positive controls, ‘‘CLP+EGCG’’; n=2, P,0.01)
and KC (26.5613.5% of positive controls, ‘‘CLP+Saline’’; versus
11.468.6% of positive controls, ‘‘CLP+EGCG’’; n=2, P,0.05). To
evaluate the significance of IL-6 and KC in predicting outcome of
lethal sepsis [34], we compared their circulating levels in dying (in
a moribund state) versus non-dying (in a non-moribund state) septic
mice at 52 h post CLP. Circulating levels of IL-6 and KC, as well as
Figure 3. Delayed administration of EGCG still significantly attenu-
ated endotoxin-induced HMGB1 release. Murine macrophage-like
RAW 264.7 cells were stimulated with LPS, and EGCG (10 mM) was
added at 0, 2, 6, and 12 hours post LPS stimulation. Levels of HMGB1
levels in the culture medium were determined at 16 hours after LPS
stimulation, and expressed (in arbitrary unit, AU) as mean6S.D. of two
independent experiments (N=2). Shown in the lower panel was
a representative Western blot. *, P,0.05 versus controls (‘‘+ LPS alone’’).
doi:10.1371/journal.pone.0001153.g003
Figure 4. EGCG, but not catechin or ethyl gallate, effectively
abrogated endotoxin-induced HMGB1 release. Macrophage cultures
were stimulated with LPS in the absence, or presence of epigalloca-
techin gallate (EGCG), catechin (C), or ethyl gallate (G) (Panel A), and
assayed for HMGB1 release by Western blotting analysis (Panel B)a t
16 h post LPS stimulation. Note that epigallocatechin gallate, but not
catechin or ethyl gallate, abrogated LPS-induced HMGB1 release.
doi:10.1371/journal.pone.0001153.g004
Figure 5. EGCG significantly protects mice against lethal endotox-
emia (Panel A) and lethal sepsis (Panel B). Balb/C mice were subjected
to lethal endotoxemia (LPS, 15 mg/kg, i.p., Panel A), or sepsis (induced
by CLP, Panel B). At 20.5, +24, and +48 hours post the onset of
endotoxemia, or +24, +48, +72 hours post the onset of sepsis, animals
were intraperitoneally administered with saline (0.2 ml/mouse), or
EGCG (0.2 ml/mouse, at indicated doses), and animal survival was
monitored for up to two weeks. The Kaplan-Meier method was used to
compare the differences in mortality rates between groups. *, P,0.05
versus saline.
doi:10.1371/journal.pone.0001153.g005
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moribund’’, Fig. 6B, middle panel) were markedly higher than
those in healthy mice (‘‘-CLP’’, Fig. 6B, left Panel), but
dramatically lower than those in non-dying septic mice (‘‘+ CLP,
non-moribund’’, Fig. 6B, right panel). It confirms the notion that
plasma levels of IL-6, KC, MIP-2, and TNF soluble receptor I
(sTNFR-I) werereliablepredictorsoflethaloutcomeinexperimental
[34,35], or clinical sepsis [36].
Although delayed administration of EGCG did not attenuate
circulating TNF levels at 52 h after the onset of sepsis (Fig. 6C,
left panel), it did significantly attenuate circulating levels of
HMGB1 (Fig. 6C, right panel, P,0.05), suggesting that EGCG
confers protection against lethal sepsis partly by attenuating
systemic HMGB1 accumulation.
EGCG inhibits HMGB1-induced cytokine release
To elucidate additional mechanisms underlying EGCG-mediated
protection, we determined whether EGCG inhibits HMGB1-
mediated inflammatory response. Indeed, EGCG dose-depen-
dently inhibited HMGB1-induced TNF release in murine
macrophage-like RAW 264.7 cells (Fig. 7A, top panel). Despite
the fact that EGCG failed to inhibit LPS-induced nitric oxide
(Fig. 1C), it dose-dependently suppressed HMGB1-induced
release of nitric oxide in RAW 264.7 cells (Fig. 7A, bottom
panel), or primary MuMACs (Fig. 7B), supporting the notion that
LPS and HMGB1 use distinct mechanisms to activate innate
immune cells [29,37]. Furthermore, EGCG effectively inhibited
HMGB1-induced release of IL-6 release, even when it was given
2–4 hours after HMGB1 stimulation (Fig. 7C, and data not
Figure 6. EGCG attenuates sepsis-induced systemic accumulation of IL-6, KC, and HMGB1. Balb/C mice were subjected to lethal sepsis by CLP, and
intraperitoneally administered with control saline (0.2 ml/mouse) or EGCG (4.0 mg/kg) at +24, +48 hours post CLP. At 52 hours post the onset of
sepsis, serum levels of cytokines (Panel A, B, C), or HMGB1 (Panel C) were determined by cytokine antibody array (Panel A, B), ELISA (Panel C), or
Western blotting analysis (Panel C), respectively. In parallel experiments, serum were pooled from 3 normal mice (-CLP), 3 septic mice approaching
moribund state (52 h post CLP), 3 septic mice in non-moribund state (52 h post CLP), and assayed for cytokine profile by antibody array (Panel B).
Serum levels of HMGB1 or TNF (Panel C) were expressed as mean6SD (n=8–10). *, P,0.05 (ANOVA, Tukey test).
doi:10.1371/journal.pone.0001153.g006
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protection against lethal sepsis partly by inhibiting HMGB1
cytokine activities.
EGCG prevents clustering of exogenous HMGB1 on
macrophage cell surface
Engagement of LPS to cell-surface receptor (such as CD14, TLR4)
induces clustering of ligand/receptor complexes (consisting of
TLR4, hsp70, hsp90, CXCR4, and GDF5) at the cell surface
[38], which is critical for signaling transduction, as receptor
clustering-disrupting agents (such as nystatin or MCD) prevent
LPS-induced cytokine production [38]. To gain insight into the
mechanismbywhichEGCGattenuatesHMGB1-mediated cytokine
production, we first determined whether exogenous HMGB1
accumulates and clusters on macrophage cell surface. Biotin-labeled
recombinant HMGB1 was used to distinguish exogenous (CBP-
HMGB1 fusion) from endogenous HMGB1 protein. In the absence
of exogenous HMGB1, staining with streptavidin-conjugated Alexa
488 or Alexa594 revealed weak and diffuse background fluorescence
throughout the cytoplasmic region (Fig. 8A, 8B, ‘‘- HMGB1’’). At
2-6 h post HMGB1 treatment, staining with streptavidin-Alexa 594
showed strong, punctuate fluorescence predominantly on macro-
phage cell surface (Fig. 8A, ‘‘Streptavidin Alexa 594’’). These Alexa
594-associated red fluorescence co-localized with green fluorescence
produced with HMGB1-specific antibodies (Fig. 8A, ‘‘Anti-
HMGB1 Alexa 488’’, and ‘‘Overlay’’), indicating that exogenous
HMGB1 accumulates and clusters on macrophage cell surface in
a time-dependent fashion. Intriguingly, this HMGB1-induced self
clustering coincided with the kinetics of HMGB1-mediated cytokine
release (e.g., TNF), which begins at 4-6 h, and peaks around 16 h
post HMGB1 stimulation (data not shown).
To further elucidate the mechanism by which EGCG attenuates
HMGB1-mediated cytokine production, we determined whether
Figure 7. EGCG attenuates HMGB1-induced release of proinflammatory mediators. Murine macrophage-like RAW 264.7 cells (Panel A, Panel C) or
primary murine peritoneal macrophages (Panel B) were stimulated with HMGB1 (2.0 mg/ml) in the absence, or presence of EGCG added at indicated
concentrations, and time points post HMGB1 stimulation. At 16 hours after HMGB1 stimulation, levels of TNF (Panel A, B, top), IL-6 (Panel C), nitric
oxide (Panel A, B, bottom) in the culture medium were determined by ELISA or Griess reaction (Panel A, B), respectively.
doi:10.1371/journal.pone.0001153.g007
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PLoS ONE | www.plosone.org 7 November 2007 | Issue 11 | e1153Figure 8. EGCG prevents HMGB1 accumulation/clustering on macrophage cell surface. Macrophage cultures were incubated with biotin-labeled CBP-
HMGB1 fusion protein (‘‘+ HMGB1’’, 2 mg/ml), in the absence (Panel A), or presence (Panel B, C) of EGCG (10 mM) for various period of time. To visualize
exogenousHMGB1,cellswerestainedwithstreptavidin-conjugatedAlexa594(Panel A, ‘‘StreptavidinAlexa594’’)orAlexa488(Panel B, ‘‘StreptavidinAlexa
488’’ ), or HMGB1-specific rabbit antibodies plus Alexa 488-conjugated goat-anti-rabbit antibodies (Panel A, ‘‘Anti-HMGB1 Alexa 488’’). Phase contras
images indicate macrophage cell morphology; overlay images show co-localization of red and green fluorescence (as yellow). Note anti-HMGB1 antibody-
specific immunostaining revealed the presence of both exogenous (on cell surface) and endogenous HMGB1 (in the nucleus) at 4–6 hours post HMGB1
incubation (Panel A, ‘‘Anti-HMGB1 Alexa 488’’). To determine the relative content of exogenous HMGB1, streptvidin-pulled down fraction or whole cell
lysate were immunoblotted with HMGB1-specific antibodies (Panel C). Note EGCG dramatically decreased levels of exogenous HMGB1 (indicated by the
33 kDa band corresponding to CBP-HMGB1 fusion protein) (‘‘rHMGB1’’).
doi:10.1371/journal.pone.0001153.g008
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macrophage cell surface. Indeed, in the presence of EGCG
(10 mM), HMGB1-induced cell surface clustering, as indicated by
Alexa 488-associated cell surface fluorescence, was almost
completely eliminated (Fig. 8B), suggesting that EGCG prevents
HMGB1 accumulation on macrophage cell surface. To test this
possibility, we assayed macrophage whole-cell lysate or streptavi-
din pull-down fraction for content of exogenous HMGB1 by
Western blotting analysis. As expected, at 6 hours following
HMGB1 incubation, levels of exogenous HMGB1 in macrophage
whole-cell lysate or streptavidin-pulled-down fractions were
increased in the presence of exogenous HMGB1 (‘‘+rHMGB1’’,
Fig. 8C), but dramatically decreased in the presence of EGCG
(‘‘+rHMGB1+EGCG’’, Fig. 8C).
DISCUSSION
We recently discovered that green tea, brewed from the leaves of
the plant, Camellia sinensis, is effective in inhibiting bacterial
endotoxin-induced HMGB1 release [31], but the active compo-
nents responsible for its activities were previously unknown. Here
we report that a major component, EGCG, recapitulated
HMGB1-inhibiting activities of green tea, and dose-dependently
inhibited LPS-induced HMGB1 release in macrophage/monocyte
cultures. At concentrations that completely abrogated LPS-
induced HMGB1 release, EGCG did not affect LPS-induced
nitric oxide release, but only partially attenuated LPS-induced
TNF secretion. These data contradict with some reports [39,40],
but agree with several other observations [32,33]. The underlying
causes for this discrepancy are unknown, and may be partly
attributable to EGCG’s chemical properties, which can sponta-
neously dimerize to liberate immunostimulatory products (such as
hydrogen peroxide) [10,41].
The mechanism underlying EGCG-mediated suppression of
HMGB1 release remains elusive. For instance, it is not known
whether EGCG-mediated suppression of HMGB1 release is
dependent on its antioxidant activities, because some antioxidants
(e.g., catechin, ethyl gallate) failed to inhibit LPS-induced HMGB1
release. Similarly, it is not yet known whether EGCG inhibits LPS-
induced HMGB1 release through inhibiting LPS-induced cyto-
plasmic translocation, or post-translational modification (such as
acetylation or phosphorylation). Interestingly, it has been
suggested that EGCG can bind to lipid raft-associated cell surface
receptor (e.g., the 67 kDa laminin receptor, 67LR) to confer its
anti-cancer properties [42,43], or anti-inflammatory allergic
response [44,45]. LPS can induce clustering of ligand/receptor
complexes (containing hsp70, hsp90, CXCR4, GDF5 and TLR4)
within membrane macrodomain (lipid rafts), which transmit
signals to active macrophages to produce various proinflammatory
mediators [38]. Since receptor clustering-disrupting agents (such
as nystatin or MCD) can prevent LPS-induced cytokine pro-
duction [38], it will thus be interesting to determine whether
EGCG inhibits HMGB1 release via similar mechanisms.
Once released, extracellular HMGB1 employs several cell
surface receptors (such as TLR2, TLR4, or RAGE) to activate
innate immune cells to produce pro-inflammatory cytokines [46–
49]. Indeed, fluorescence resonance energy transfer (FRET)
analysis has demonstrated a close physical interaction between
HMGB1 and TLR2 or TLR4 on macrophage cell surface within
5-15 minutes of HMGB1 incubation [47], long before subsequent
HMGB1-induced cytokine release. Intriguingly, we observed
a time-dependent accumulation of exogenous HMGB1 clustering
on macrophage cell surface within 2–6 hours of HMGB1
incubation, which correlates with the kinetics of HMGB1-induced
release of proinflammatory cytokines [29]. On the other hand,
EGCG dose-dependently inhibited cell surface clustering of
exogenous HMGB1, and consequently attenuated HMGB1-
induced release of proinflammatory mediators (e.g., TNF, IL-6,
and NO). Consistently, agents (e.g., catechin or ethyl gallate)
incapable of inhibiting HMGB1-cell surface clustering uniformly
failed to inhibit HMGB1-mediated cytokine production. We thus
propose that HMGB1 may induce potential ligand/receptor (e.g.,
TLR2, TLR4, or RAGE) clustering on macrophage cell surface,
which may be a prerequisite for HMGB1-mediated macrophage
activation. Given the diverse range of receptors (e.g., TLR2,
TLR4, or RAGE) involved in HMGB1 recognition [7,50,51], it is
intriguing to investigate whether binding of HMGB1 to different
receptors leads to combinational clustering of different receptors
(such as TLR2 or TLR4) within the lipid rafts [38,52,53].
Nevertheless, our present study suggests a novel mechanism by
which EGCG prevents HMGB1-mediated cytokine production–
potentially by interfering with HMGB1-induced ligand/receptor
clustering. Although EGCG-mediated suppression of HMGB1 cell
surface clustering may not account for its inhibitory effects on
LPS-induced HMGB1 release, it likely underlies its inhibitory
effects on cytokine activities of the secreted HMGB1.
In light of the capacity of EGCG in inhibiting LPS-induced
HMGB1 release and cytokine activities, we explored its efficacy in
animal models of lethal endotoxemia and sepsis (induced by cecal
ligation and puncture). Consistent with a previous observation that
green tea polyphenols confer protection at 24 h post onset of
endotoxemia [32], we found that EGCG promoted significant,
and long-lasting protection against lethal endotoxemia. More
importantly, delayed and repeated administration of EGCG,
beginning at 24 h after onset of sepsis, significantly rescued mice
from lethal sepsis, supporting a therapeutic potential of EGCG in
the clinical management of human sepsis.
The pathogenesis of lethal sepsis remains obscure, but is
mediated in part by excessive release of early (e.g., TNF and IL-1)
and late (e.g., HMGB1) proinflammatory cytokines. Appearing
relatively early in the circulation, TNF plays a protective role in
sepsis [54], and its circulating levels do not correlate with lethality
of experimental sepsis [34,35,55]. In contrast, dys-regulated
inflammatory response sustained by late-acting mediators (such
as HMGB1) may be more pathogenic in lethal sepsis. Because
EGCG could inhibit LPS-induced TNF release in vitro,w e
strategically administered EGCG in a delayed fashion (at 24 h
post CLP) to preserve a potentially beneficial early TNF response.
Consequently, delayed administration of EGCG did not affect
circulating levels of TNF at late stage of sepsis, but specifically
attenuated systemic accumulation of HMGB1, as well as IL-6 and
KC-two most reliable surrogate markers of lethal sepsis [34,35]. In
contrast to HMGB1, IL-6 and KC may not critically important in
the pathogenesis of sepsis, because neither anti-IL-6 nor anti-KC
antibodies confer long-lasting protection against lethal sepsis
[56,57]. Therefore, we propose that EGCG rescues mice from
lethal sepsis partly through inhibiting systemic HMGB1 accumu-
lation, as well as HMGB1-induced release IL-6 and KC.
In conclusion, we demonstrated a major tea component,
EGCG, recapitulated green tea’s HMGB1-inhibiting activities,
and dose-dependently abrogated LPS-induced HMGB1 release in
macrophage/monocyte cultures. Its beneficial effects in experi-
mental sepsis were partly attributable to: 1) attenuation of systemic
accumulation of proinflammatory mediator (e.g., HMGB1) and
surrogate markers (e.g., IL-6 and KC) of lethal sepsis; and 2)
suppression of HMGB1-mediated inflammatory responses by
preventing accumulation of exogenous HMGB1 on macrophage
cell surface. The doses of EGCG given to septic mice (4 mg/kg,
i.e., 10 mM) are much higher than those readily available in
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58.
However, concentrated forms of de-caffeinated green tea extracts
or purified EGCG are commercially available, and an individual
does not need to drink multiple cups of tea everyday to enjoy the
health benefits that green tea confers. It will be possible and
important to evaluate the therapeutic potential of tea catechins
(such as EGCG) for patients with lethal sepsis or other
inflammatory diseases in future studies.
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